BARD1 Life Sciences

About:

BARD1 Life Sciences Ltd is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests

Website: https://www.bard1.com/

Twitter/X: BARD1LSL

Top Investors: Venture Kick

Description:

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

Total Funding Amount:

$18.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Nedlands, Western Australia, Australia

Founded Date:

1983-01-01

Contact Email:

info(AT)bard1.com

Founders:

Irmgard Irminger-Finger

Number of Employees:

11-50

Last Funding Date:

2021-07-23

IPO Status:

Public

Industries:

© 2025 bioDAO.ai